Skip to main content
SpringerLink
Log in

Treatment of Uveitis with Intraocular Steroids

  • Chapter
  • First Online:
Intravitreal Steroids

  • 624 Accesses

Abstract

Uveitis, or inflammation inside the eye, is a relatively uncommon disease. Still it accounts for 10–15 % of all causes of blindness among people of working age in the developed world. Uveitis can be categorized according to anatomical involvement or by etiology such as infectious or noninfectious. In order to maintain normal visual function, the eye must remain an immune-privileged site to which immune cells have restricted access and function. Dysfunction of these immunosuppressive mechanisms results in an uncontrolled intraocular immune response that can lead to irreversible structural damage and loss of visual function. Corticosteroids are the cornerstone treatment for patients with noninfectious uveitis. While they are effective in controlling inflammation, systemic corticosteroids can result in side effects that limit their use. This has prompted the development and use of local steroid treatment in the form of intravitreal steroid injections and intraocular implants. These provide high steroid concentration inside the eye, are effective, and minimize systemic effects. In this chapter, we review the use of intraocular steroids for the treatment of uveitis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2013;131:1405–12.

    Article  PubMed  Google Scholar 

  2. Suhler EB, Lloyd MJ, Choi D, Rosenbaum JT, Austin DF. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol. 2008;146:890–6.e8.

    Article  PubMed  Google Scholar 

  3. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303–8.

    Article  CAS  PubMed  Google Scholar 

  4. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80:844–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Kaiser CJ, Ksander BR, Streilein JW. Inhibition of lymphocyte proliferation by aqueous humor. Reg Immunol. 1989;2:42–9.

    CAS  PubMed  Google Scholar 

  6. Apte RS, Niederkorn JY. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol. 1996;156:2667–73.

    CAS  PubMed  Google Scholar 

  7. Dace DS, Chen PW, Niederkorn JY. CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology. 2008;123:367–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Sun D, Enzmann V, Lei S, Sun SL, Kaplan HJ, Shao H. Retinal pigment epithelial cells activate uveitogenic T cells when they express high levels of MHC class II molecules, but inhibit T cell activation when they express restricted levels. J Neuroimmunol. 2003;144:1–8.

    Article  CAS  PubMed  Google Scholar 

  9. Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40:3177–85.

    CAS  PubMed  Google Scholar 

  10. Takeuchi M, Yokoi H, Tsukahara R, Sakai J, Usui M. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis. Jpn J Ophthalmol. 2001;45:463–9.

    Article  CAS  PubMed  Google Scholar 

  11. Sugita S, Futagami Y, Smith SB, Naggar H, Mochizuki M. Retinal and ciliary body pigment epithelium suppress activation of T lymphocytes via transforming growth factor beta. Exp Eye Res. 2006;83:1459–71.

    Article  CAS  PubMed  Google Scholar 

  12. Mochizuki M, Sugita S, Kamoi K. Immunological homeostasis of the eye. Prog Retin Eye Res. 2013;33:10–27.

    Article  CAS  PubMed  Google Scholar 

  13. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30:452–70.

    Article  PubMed  Google Scholar 

  14. Chen L, Yang P, Zhou H, et al. Diminished frequency and function of CD4+CD25high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49:3475–82.

    Article  PubMed  Google Scholar 

  15. Hamzaoui K, Hamzaoui A, Houman H. CD4+CD25+ regulatory T cells in patients with Behcet’s disease. Clin Exp Rheumatol. 2006;24:S71–8.

    CAS  PubMed  Google Scholar 

  16. Chi W, Zhu X, Yang P, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49:3058–64.

    Article  PubMed  Google Scholar 

  17. Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol. 2011;163:29–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Fischer S, Renz D, Schaper W, Karliczek GF. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol. 2001;411:231–43.

    Article  CAS  PubMed  Google Scholar 

  19. Tomkins-Netzer O, Taylor SR, Lightman S. Corticosteroid-sparing agents: new treatment options. Dev Ophthalmol. 2012;51:47–56.

    Article  CAS  PubMed  Google Scholar 

  20. Friedlaender MH. Corticosteroid therapy of ocular inflammation. Int Ophthalmol Clin. 1983;23:175–82.

    Article  CAS  PubMed  Google Scholar 

  21. Mondino BJ, Farley MK, Aizuss DH. Sectorial corneal infiltrates and pannus in herpes zoster ophthalmicus. Graefe’s Arch Clin Exp Ophthalmol Albrecht Graefes Archiv Klin Exp Ophthalmol. 1986;224:313–6.

    Article  CAS  Google Scholar 

  22. Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22:517–22.

    Article  PubMed  Google Scholar 

  23. Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004;32:563–8.

    Article  Google Scholar 

  24. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916 e1–7.

    Article  Google Scholar 

  25. Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42:81–6.

    Article  CAS  PubMed  Google Scholar 

  26. Inoue M, Takeda K, Morita K, Yamada M, Tanigawara Y, Oguchi Y. Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection. Am J Ophthalmol. 2004;138:1046–8.

    Article  CAS  PubMed  Google Scholar 

  27. Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand. 2006;84:722–33.

    Article  CAS  PubMed  Google Scholar 

  28. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters 3rd GB, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681–6.

    Article  PubMed  Google Scholar 

  29. Gan IM, Ugahary LC, van Dissel JT, van Meurs JC. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefe’s Arch Clin Exp Ophthalmol Albrecht Graefes Archiv Klin Exp Ophthalmol. 2005;243:1186–9.

    Article  CAS  Google Scholar 

  30. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol. 1992;110:259–66.

    Article  CAS  PubMed  Google Scholar 

  31. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171–80.

    PubMed Central  CAS  PubMed  Google Scholar 

  32. Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology. 2009;116:902–11; quiz 12–13.

    Article  PubMed  Google Scholar 

  33. Cakir M, Dogan M, Bayraktar Z, et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina (Phila, Pa). 2008;28:465–72.

    Article  Google Scholar 

  34. Conti SM, Kertes PJ. The use of intravitreal corticosteroids, evidence-based and otherwise. Curr Opin Ophthalmol. 2006;17:235–44.

    Article  PubMed  Google Scholar 

  35. Das-Bhaumik RG, Jones NP. Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye (London, England). 2006;20:934–7.

    Article  CAS  Google Scholar 

  36. Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocul Immunol Inflamm. 2014;22:27–33.

    Article  CAS  PubMed  Google Scholar 

  37. Moreker MR, Lodhi SA, Pathengay A. Role of intravitreal triamcinolone as an adjuvant in the management of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2007;55:479–80.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Wadhwa N, Garg SP, Mehrotra A. Prospective evaluation of intravitreal triamcinolone acetonide in serpiginous choroiditis. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2010;224:183–7.

    Article  CAS  Google Scholar 

  39. Moschos MM, Gatzioufas Z, Margetis I. Intravitreal triamcinolone acetonide for macular edema in HLA-B27 negative ankylosing spondylitis. Case Rep Ophthalmol. 2010;1:105–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001;29:2–6.

    Article  CAS  Google Scholar 

  41. Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008;126:200–5.

    Article  PubMed  Google Scholar 

  42. Lasave AF, Zeballos DG, El-Haig WM, Díaz-Llopis M, Salom D, Arevalo JF. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm. 2009;17:423–30.

    Article  CAS  PubMed  Google Scholar 

  43. Soheilian M, Rabbanikhah Z, Ramezani A, Kiavash V, Yaseri M, Peyman GA. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2010;26:199–206.

    Article  CAS  Google Scholar 

  44. Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomised eye. Br J Ophthalmol. 2006;90:705–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004;122:336–40.

    Article  CAS  PubMed  Google Scholar 

  46. Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol (Copenh). 2012;90:e323–5.

    Article  Google Scholar 

  47. Lorenzo Carrero J, González Barcia M, Pérez Flores I. Sterile endophthalmitis after benzyl alcohol filtered triamcinolone acetonide injection. Arch Ophthalmol. 2008;126:142–3.

    Article  PubMed  Google Scholar 

  48. Jager RD, Aiello LP, Patel SC, Cunningham Jr ET. Risks of intravitreous injection: a comprehensive review. Retina (Phila, Pa). 2004;24:676–98.

    Article  Google Scholar 

  49. Cheung CSY, Wong AWT, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609–14.

    Article  PubMed  Google Scholar 

  50. Takakura A, Tessler HH, Goldstein DA, et al. Viral retinitis following Intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. Ocul Immunol Inflamm. 2014;22:175–82.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Rush R, Sheth S. Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration. Indian J Ophthalmol. 2012;60:141–3.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Chang-Lin J-E, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–6.

    Article  CAS  PubMed  Google Scholar 

  53. London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28:351–66.

    Article  CAS  PubMed  Google Scholar 

  54. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009;147:1048–54, 54.e1–2.

    Article  CAS  PubMed  Google Scholar 

  55. Lowder C, Belfort Jr R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545–53.

    Article  PubMed  Google Scholar 

  56. Tomkins-Netzer O, Taylor SRJ, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121:1649–54.

    Article  PubMed  Google Scholar 

  57. Taylor SR, Tomkins-Netzer O, Joshi L, Morarji J, McLoone E, Lightman S. Dexamethasone implant in pediatric uveitis. Ophthalmology. 2012;119:2412–e2.

    Article  PubMed  Google Scholar 

  58. Kumari N, Parchand S, Kaushik S, Singh R. Intractable glaucoma necessitating dexamethasone implant (ozurdex) removal and glaucoma surgery in a child with uveitis. BMJ Case Rep. 2013;Epub.

    Google Scholar 

  59. Bansal R, Bansal P, Kulkarni P, Gupta V, Sharma A, Gupta A. Wandering ozurdex® implant. J Ophthal Inflamm Infect. 2011;2:1–5.

    Article  Google Scholar 

  60. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2004;20:269–75.

    Article  CAS  Google Scholar 

  61. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113:1020–7.

    Article  PubMed  Google Scholar 

  62. Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118:1916–26.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Rush RB, Goldstein DA, Callanan DG, Meghpara B, Feuer WJ, Davis JL. Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. Am J Ophthalmol. 2011;151:630–6.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Mahajan VB, Gehrs KM, Goldstein DA, Fischer DH, Lopez JS, Folk JC. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology. 2009;116:552–7.e1.

    Article  PubMed  Google Scholar 

  65. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology. 2010;117:567–75, 75.e1.

    Article  PubMed  Google Scholar 

  66. Friedman DS, Holbrook JT, Ansari H, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013;120:1571–9.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Inc. BL. Retisert (fluocinolone acetonide intravitreal implant) 0.59 mg for intravitreal use: US prescribing information. 2011. Bausch & Lomb Incorporated Rochester, NY.

    Google Scholar 

  68. Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (retisert) and dexamethasone (ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2013;29:501–7.

    Article  CAS  Google Scholar 

  69. Vasconcelos-Santos DV, Nehemy PG, Schachat AP, Nehemy MB. Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide: incidence and risk factors. Retina (Phila, Pa). 2008;28:573–80.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Ophthalmology, University College London/Moorfields Eye Hospital, 162 City Road, London, EC1V 2PD, UK

    Lazha Talat MBChB, MPH, MSc & Filis Ismetova MD, MPH

  2. UCL/Institute of Ophthalmology and Moorfields Eye Hospital, 162 City Road, London, EC1V 2PD, UK

    Susan Lightman FRCP (UK), PhD FRCOphth & Oren Tomkins-Netzer MD, PhD

Authors
  1. Lazha Talat MBChB, MPH, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filis Ismetova MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susan Lightman FRCP (UK), PhD FRCOphth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oren Tomkins-Netzer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lazha Talat MBChB, MPH, MSc .

Editor information

Editors and Affiliations

  1. Städt. Klinikum Karlsruhe, Augenklinik, Karlsruhe, Germany

    Albert J. Augustin

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Talat, L., Ismetova, F., Lightman, S., Tomkins-Netzer, O. (2015). Treatment of Uveitis with Intraocular Steroids. In: Augustin, A. (eds) Intravitreal Steroids. Springer, Cham. https://doi.org/10.1007/978-3-319-14487-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14487-0_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14486-3

  • Online ISBN: 978-3-319-14487-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation